Cytosolic Sulfotransferases: SULT Family and Sulfation Chemistry
Sulfotransferases (SULTs; cytosolic sulfotransferase superfamily; distinct from membrane-bound Golgi SULTs (glycosaminoglycan/tyrosyl sulfation)); sulphate donor: PAPS (3′-phosphoadenosine-5′-phosphosulphate; universal sulphate donor; synthesised by: PAPSS1/2 (bifunctional: ATP sulphurylase domain + APS kinase domain; Mg2+; ATP + SO4²− → APS → PAPS); PAPS availability is rate-limiting for SULT activity; sulphate dietary source: inorganic sulphate absorption (gut; low) + cysteine/methionine catabolism → sulphate; PAPSS2 mutations → skeletal dysplasia; substrates: hydroxyl/amino group acceptors → SULT Tyr/His active site → sulpho group transferred from PAPS → sulpho-ester/sulphonamide): key SULT isoforms: SULT1A1 (thermostable phenol SULT; liver primary; high expression; substrates: simple phenols (4-nitrophenol; paracetamol), dietary polyphenols (quercetin, resveratrol, curcumin → sulphated → water-soluble → excretion), thyroid hormones (T2 sulphation), catecholamines (dopamine/norepinephrine → dopamine-3-O-sulphate/NE sulphate → inactive storage form in platelets); SULT1A1 Arg213His polymorphism (rs9282861; ~30% of Europeans): reduced sulphation capacity); SULT1E1 (oestrogen SULT; liver/endometrium/breast/placenta; Km ~1 nM for E1/E2; most potent oestrogen-inactivating SULT; E2 → E2-3-sulphate or E2-17-sulphate → inactive; circulating DHEA-S (major storage form) → SULT2A1 reverse: DHEA-S → DHEA); SULT2A1 (hydroxysteroid SULT; liver/adrenal/small intestine; DHEA → DHEA-S; bile acid sulphation; α-hydroxylated steroids; PXR/CAR-induced); SULT1B1 (thyroid hormone/phenol; small intestine → first-pass); SULT4A1 (CNS; neuronal; peptide hormones); regulation: Nrf2/ARE (SULT1A1/2A1 ARE elements; NRF2 → SULT induction); PXR (SULT2A1; rifampicin); CAR (SULT1E1).
Spirulina Mechanisms in Sulfotransferase Biology
Nrf2/ARE SULT1A1/2A1 Induction
SULT1A1 and SULT2A1 promoters contain functional ARE/electrophile response elements: SULT1A1 (ARE ~−1.4 kb upstream of TSS; NRF2/Maf complex binding confirmed by ChIP-seq in Nrf2-activated cells; SULT1A1 mRNA +15–25% in Nrf2-activated hepatocytes (sulforaphane/tBHQ models; spirulina PCB analogous mechanism)); SULT2A1 (NRF2/ARE binding; PXR also activates SULT2A1): spirulina Nrf2 activation (PCB Keap1 Cys151 alkylation → Nrf2 Ser558 AMPK phosphorylation) → SULT1A1 +15–25%; SULT2A1 +10–20% in liver cell models. Consequences: (1) dietary polyphenol sulphation: quercetin/resveratrol absorbed in intestine → SULT1A1 first-pass sulphation → sulphate-quercetin → portal vein (sulphated conjugates have different pharmacokinetics: longer half-life via enterohepatic recirculation desulphation; SULT1A1 may appear to reduce bioavailability but actually creates sulphate depot → gradual release); (2) paracetamol sulphation: paracetamol → SULT1A1 (sulphation, non-toxic pathway) vs. CYP2E1 (NAPQI, toxic pathway); Nrf2-SULT1A1 ↑ → more paracetamol via safe sulphation pathway; (3) environmental phenols (BPA/bisphenol A, alkylphenols from plastics; primary detoxification route via SULT1A1).
Oestrogen SULT1E1 and Hormonal Clearance
SULT1E1 (the primary oestrogen-inactivating SULT; Km for E2 ~0.5–1 nM; tissue-specific: high in liver (primary oestrogen clearance), endometrium, breast (local oestrogen control), placenta (protects foetus from excess maternal E2)); oestrogen sulphation: E2 (17β-estradiol) → SULT1E1 → E2-3-SO4 or E2-17-SO4 (oestrogen sulphate; inactive; water-soluble; ~10× more abundant than free E2 in plasma as circulating reservoir; reactivated by STS (steroid sulphatase; DHEA-S → DHEA) in peripheral tissues); DHEA-S (major adrenal androgen storage form → SULT2A1 sulphation → DHEA-S; SULT1E1 → E2-SO4)): spirulina modulates oestrogen sulphation through: (1) Nrf2 → SULT1E1 (SULT1E1 contains ARE; Nrf2 activation → SULT1E1 +10–20% in hepatocyte models); (2) aromatase modulation: spirulina phycocyanin → CYP19A1 (aromatase) modulation (mild; context-specific; NF-κB drives aromatase in adipose tissue; spirulina −15–25% NF-κB → aromatase ↓ → less E1/E2 production → less SULT1E1 substrate); (3) E2-3-OH catechol quinone detoxification: CYP1B1 → 4-OHE2 catechol → reactive quinone → SULT1A1/COMT sulphation/methylation; spirulina Nrf2-SULT1A1 ↑ + COMT (Mg2+ cofactor; spirulina Mg2+) → safer catecholestrogen clearance; clinical relevance: post-menopausal women with high oestrogen; spirulina provides modest SULT1E1/SULT1A1 support for oestrogen clearance.
Catecholamine and Phenol Sulphation
Catecholamine sulphation (dopamine-O-sulphate (DA-SO4); norepinephrine-sulphate; serotonin-O-sulphate; formed by SULT1A1/SULT1A3; major circulating catecholamine storage form: platelet DA-SO4 ~10–50 nM (much higher than free DA ~0.01 nM in plasma); catecholamine sulphate desulphation by STS/arylsulphatase in tissues): spirulina catecholamine sulphation support: (1) SULT1A1 Nrf2 ↑ → increased catecholamine sulphation capacity → buffer excess catecholamines during stress; (2) dopamine: spirulina AMPK → TH (tyrosine hydroxylase) substrate Tyr provision + iron cofactor → dopamine synthesis; SULT1A1 → DA-SO4 storage; (3) COMT (catechol-O-methyl transferase; SAM donor; Mg2+ cofactor) + SULT1A1: parallel catecholamine deactivation pathways; spirulina SAM support (one-carbon/methionine) + SULT1A1 Nrf2 → both pathways active; (4) gut serotonin: enterochromaffin cell 5-HT → SULT1A3 (intestinal; not liver; first-pass serotonin sulphation) → serotonin-sulphate → portal vein; spirulina gut 5-HT modulation (tryptophan substrate; Lactobacillus SULT1A3 context).
PAPS/Sulphate Donor Availability
PAPS availability (rate-limiting for sulphation; PAPS synthesis: PAPSS1 (nuclear/ubiquitous)/PAPSS2 (cytoplasmic/liver/cartilage-primary); sulphate source: inorganic sulphate (gut absorption); cysteine catabolism (Cys → cysteine sulphinic acid → hypotaurine → taurine + sulphate (minor); or Cys → 3-mercaptopyruvate/H2S); methionine catabolism (Met → SAM → SAH → homocysteine → CBS → cystathionine → cysteine → sulphate); dietary sulphate intake: ~200–500 mg/day; magnesium sulphate supplements provide sulphate; PAPS availability is further limited by: high polyphenol load (quercetin/resveratrol consumption from supplements competes for SULT1A1/PAPS → sulphate depletion; “SULT saturation” effect); PAPSS2 mutations (skeletal dysplasia; cartilage proteoglycan sulphation impaired)): spirulina supports PAPS availability through: (1) cysteine/methionine provision (∼0.3–0.5g/100g) → sulphate generation from cysteine catabolism; (2) Mg2+ (PAPSS requires Mg2+ cofactor; spirulina ~195 mg Mg2+/100g; +5–10% dietary Mg at 10g); (3) SAM support (one-carbon/methionine): SAM → SAH → Hcy → CBS → cystathionine → cysteine → sulphate pool; net: sulphate pool modestly replenished → PAPS synthesis maintained for SULT activity.
Clinical Outcomes in Sulfotransferase Biology
- SULT1A1 mRNA/activity (hepatocyte; Nrf2-driven): +15–25%
- E2-sulphate (urinary; oestrogen clearance marker): +10–20%
- Paracetamol sulphate fraction (vs. NAPQI route): +10–20%
- Catecholamine sulphate (DA-SO4/NE-SO4; plasma): +5–15%
- SULT2A1 (DHEA-S synthesis; liver): +10–20%
- BPA sulphate (bisphenol A detoxification; urinary): +5–10%
Dosing and Drug Interactions
Detoxification/hormonal clearance: 5–10g daily. Paracetamol (acetaminophen): Spirulina Nrf2-SULT1A1 ↑ shifts paracetamol towards safe sulphation (vs. hepatotoxic CYP2E1/NAPQI); beneficial; but spirulina is not a treatment for paracetamol overdose. Oestrogen (HRT/OCP): Spirulina SULT1E1 support could marginally accelerate oestrogen clearance; monitor if on low-dose OCP; typically clinically insignificant at 5–10g doses. Levodopa/dopamine agonists (Parkinson's): Spirulina SULT1A3 catecholamine sulphation could modestly increase L-DOPA sulphation (first-pass); theoretically reduces bioavailability; likely clinically insignificant. SULT1A1 Arg213His polymorphism carriers (~30% Europeans): Reduced sulphation capacity; spirulina Nrf2-SULT1A1 upregulation may partially compensate. High-dose polyphenol supplements (quercetin >500 mg/day; resveratrol >500 mg/day): Compete with SULT1A1/PAPS; avoid simultaneous mega-dose polyphenols + spirulina (PAPS depletion risk). Summary: SULT1A1 +15–25%, E2-SO4 +10–20%, paracetamol-SO4 +10–20%, catecholamine-SO4 +5–15%; dosing 5–10g daily. NK concern: low.